NUC-1031 in aBTC: a cautionary tale in accelerated drug development

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-23 DOI:10.1016/j.jhep.2025.05.011

Giulia Massaro, Lorenza Rimassa, Angela Lamarca

{"title":"NUC-1031 in aBTC: a cautionary tale in accelerated drug development","authors":"Giulia Massaro, Lorenza Rimassa, Angela Lamarca","doi":"10.1016/j.jhep.2025.05.011","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>The authors received no financial support to produce this manuscript.</section></section><section><section><h2>Authors' contributions</h2>GM, LR, and AL contributed to the concept of the letter. GM and AL interpreted the data and drafted the manuscript. All authors critically revised the manuscript and approved its final draft.</section></section><section><section><h2>Data availability statement</h2>Data are available on reasonable request.All authors confirm that we did not and will not submit the data included in the letter as original publication elsewhere.</section></section><section><section><h2>Declaration of Competing Interest</h2>AL: Travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan, Delcath Advanz Pharma and Roche. Speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA/Novartis, QED, Servier, Astra Zeneca, EISAI, Roche, Advanz Pharma and MSD. Advisory and consultancy honoraria from EISAI, Nutricia, Ipsen, QED, Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim, GENFIT, TransThera Biosciences, Taiho, MSD and Viatris. Principal</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"238 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.05.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Financial support

The authors received no financial support to produce this manuscript.

Authors' contributions

GM, LR, and AL contributed to the concept of the letter. GM and AL interpreted the data and drafted the manuscript. All authors critically revised the manuscript and approved its final draft.

Data availability statement

Data are available on reasonable request.All authors confirm that we did not and will not submit the data included in the letter as original publication elsewhere.

Declaration of Competing Interest

AL: Travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan, Delcath Advanz Pharma and Roche. Speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA/Novartis, QED, Servier, Astra Zeneca, EISAI, Roche, Advanz Pharma and MSD. Advisory and consultancy honoraria from EISAI, Nutricia, Ipsen, QED, Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim, GENFIT, TransThera Biosciences, Taiho, MSD and Viatris. Principal

查看原文本刊更多论文

aBTC中的nucc -1031：加速药物开发的警示故事

经济支持作者没有获得撰写本文的经济支持。作者的贡献gm， LR和AL对这封信的概念做出了贡献。GM和AL对数据进行解读并起草稿件。所有作者都严格修改了手稿，并批准了最终稿。数据可用性声明如有合理要求，可提供数据。所有作者确认，我们没有也不会将信中包含的数据作为原始出版物提交到其他地方。竞争利益宣言：来自Ipsen、辉瑞、拜耳、AAA、SirtEx、诺华、Mylan、Delcath Advanz Pharma和罗氏的旅行和教育支持。默克、辉瑞、Ipsen、Incyte、AAA/诺华、QED、施维雅、Astra Zeneca、EISAI、罗氏、Advanz Pharma和默沙东的荣誉演讲嘉宾。来自EISAI、Nutricia、Ipsen、QED、Roche、Servier、Boston Scientific、Albireo Pharma、AstraZeneca、Boehringer Ingelheim、GENFIT、TransThera Biosciences、Taiho、MSD和Viatris的咨询和顾问酬金。主要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.